InvestSMART

Immuron Limited (ASX: IMC) - Announcements

- Current share price for IMC : $0.037

ASX company news and announcements for Immuron Limited (IMC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immuron Limited (IMC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immuron Limited (IMC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immuron Limited (IMC)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$12 Form 605 - Ceasing to be Substantial Shareholder (Retzos) 8 Sep 2017 4:57PM $0.185 $0.037 fallen by 80%
$12 Appendix 4E Preliminary Final Report (30 June 2017) 31 Aug 2017 3:23PM $0.200 $0.037 fallen by 81.50%
$12 Immuron Opens Clinical Site to Commence C.Diff CDI Study 28 Aug 2017 9:57AM $0.205 $0.037 fallen by 81.95%
$12 Appendix 3Y - Change of Director's Interest Notice (PA) 28 Aug 2017 8:16AM $0.205 $0.037 fallen by 81.95%
$12 Updated Immuron Securities Trading Policy 17 Aug 2017 3:08PM $0.205 $0.037 fallen by 81.95%
$12 Appendix 3Y - Change of Director's Interest Notice (PA) 15 Aug 2017 4:17PM $0.195 $0.037 fallen by 81.03%
$12 Immuron Commences US Non-Deal Institutional Investor Roadshw 15 Aug 2017 2:42PM $0.180 $0.037 fallen by 79.44%
$12 Immuron Approved to Commence Clinical Study in C.Difficile 9 Aug 2017 9:52AM $0.180 $0.037 fallen by 79.44%
$12 Immuron to Present C.difficile Data at ClostPath 2017 Confer 8 Aug 2017 3:06PM $0.180 $0.037 fallen by 79.44%
$12 Appendix 3Y - Change of Director's Interest Notice (PA) 8 Aug 2017 1:42PM $0.180 $0.037 fallen by 79.44%
$12 Immuron Presents NASH Interim-Results at BioShares Conferenc 7 Aug 2017 10:49AM $0.190 $0.037 fallen by 80.53%
$12 Immuron Announces Management Changes 3 Aug 2017 12:27AM $0.180 $0.037 fallen by 79.44%
$12 Appendix 3B 28 Jul 2017 2:48PM $0.190 $0.037 fallen by 80.53%
$12 Success of NASH Phase II Interim Analysis Explained Further 13 Jul 2017 10:58AM $0.220 $0.037 fallen by 83.18%
$12 NASH PhaseII Interim Analysis Reveals Improved Liver Enzymes 10 Jul 2017 9:45AM $0.290 $0.037 fallen by 87.24%
$12 Pre-Clinical C. difficile Infection Results Paper Published 3 Jul 2017 10:41AM $0.280 $0.037 fallen by 86.79%
$12 Appendix 3Y - Change of Director's Interest Notice (RS) 3 Jul 2017 9:20AM $0.270 $0.037 fallen by 86.30%
$12 Change of address 26 Jun 2017 9:50AM $0.315 $0.037 fallen by 88.25%
$12 Appendix 3B - Issuance of Options (ESOP) 23 Jun 2017 11:01AM $0.290 $0.037 fallen by 87.24%
$12 Ceasing to be a substantial holder 20 Jun 2017 4:15PM $0.325 $0.037 fallen by 88.62%
$12 Change in substantial holding 20 Jun 2017 2:08PM $0.330 $0.037 fallen by 88.79%
$12 Change in substantial holding 20 Jun 2017 2:07PM $0.330 $0.037 fallen by 88.79%
$12 Change of Director's Interest Notice 20 Jun 2017 2:07PM $0.330 $0.037 fallen by 88.79%
$12 Change of Director's Interest Notice 20 Jun 2017 2:05PM $0.330 $0.037 fallen by 88.79%
$12 Change of Director's Interest Notice 20 Jun 2017 9:16AM $0.365 $0.037 fallen by 89.86%

551 - 575 of 790 results

Page 23 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.